Bristol Myers - Celgene CVRPreferred / convertible

13F holders, Q3 2025 (September 30)

Q2 2026Q1 2026Q4 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024

22holders −2

2new positions

4sold out

1famous investor

$1.00avg. 13F price*

At the end of Q3 2025, 22 institutions reported holding Bristol Myers - Celgene CVR in their 13F filings, down 2 from Q2 2025. 2 opened new positions and 4 sold out. The largest holders were Toronto Dominion Bank ($1.2M), Transcend Capital Advisors, LLC ($3K) and DAVENPORT & Co LLC ($3K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).

Company: Bristol Myers - Celgene CVR
CUSIP: 110122140
Latest filing quarter: Q2 2026

History

Number of 13F holders

Total Exit/New Position Q2 2025 → Q3 2025

	Institutions	Total Value
New Positions	2	$1.2M
Exits	4	$47K

All 13F filers, Q2 2025 → Q3 2025: 808,139 shares bought and 91,812 shares sold, net +716,327 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 22 holders


Toronto Dominion Bank	—	New	807,847	$1.2M
Transcend Capital Advisors, LLC	—	No change	109,175	$3K
DAVENPORT & Co LLC	—	No change	83,970	$3K
Bank of America Corp.	—	No change	51,828	$2K
Citadel Advisors	—	Reduce -7.4%	32,756	$1K
Susquehanna International Group, LLP	—	Reduce -32.3%	25,115	$834
Purkiss Capital Advisors LLC	—	No change	26,450	$783
Fifth Third Bancorp	—	No change	20,000	$592
Watts Gwilliam & Co., LLC	—	No change	20,000	$592
Private Advisor Group, LLC	—	No change	15,000	$444
UBS Group AG	—	Add +1.9%	13,712	$411
Two Sigma Securities, LLC	—	Reduce -42.1%	12,741	$377
Northwestern Mutual Wealth Management Co.	—	No change	341	$10
Rothschild Investment LLC	—	No change	166	$5
Morgan Stanley	—	No change	119	$4
Oakworth Capital, Inc.	—	No change	125	$4
JPMorgan Chase & Co.	—	No change	23	$1
Wells Fargo & Company	—	No change	28	$1
AE Wealth Management LLC	—	New	30	$1
First Pacific Financial	—	No change	6	$1
Atlantic Edge Private Wealth Management, LLC	—	No change	16	$1
Royal Bank of Canada	—	No change	2,475	$0

"% of holder's portfolio" is BRISTOL MYERS - CELGENE CVR's weight in each manager's 13F, not the share of Bristol Myers - Celgene CVR the manager owns.